Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A; Israeli CLL Study Group. Herishanu Y, et al. Among authors: polliack a. Haematologica. 2015 May;100(5):662-9. doi: 10.3324/haematol.2014.115808. Epub 2015 Feb 6. Haematologica. 2015. PMID: 25661442 Free PMC article.
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Joffe E, Goldschmidt N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Arad A, Polliack A, Herishanu Y; Israeli CLL Study Group. Joffe E, et al. Among authors: polliack a. Eur J Haematol. 2018 Sep;101(3):399-406. doi: 10.1111/ejh.13129. Epub 2018 Aug 3. Eur J Haematol. 2018. PMID: 29949186
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A. Herishanu Y, et al. Among authors: polliack a. Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12. Hematol Oncol. 2019. PMID: 30756414 Clinical Trial.
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N, Shapira S, Dally N, Avigdor A, Rahav G, Lustig Y, Ben David SS, Fineman R, Paz A, Bairey O, Polliack A, Levy I, Tadmor T. Benjamini O, et al. Among authors: polliack a. Haematologica. 2022 Mar 1;107(3):625-634. doi: 10.3324/haematol.2021.279196. Haematologica. 2022. PMID: 34320789 Free PMC article.
Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study Group.
Bairey O, Goldschmidt N, Ruchlemer R, Tadmor T, Rahimi-Levene N, Yuklea M, Shvidel L, Berrebi A, Polliack A, Herishanu Y; Israeli Chronic Lymphocytic Leukemia Study Group (ICLLSG). Bairey O, et al. Among authors: polliack a. Eur J Haematol. 2012 Dec;89(6):491-6. doi: 10.1111/ejh.12015. Epub 2012 Oct 26. Eur J Haematol. 2012. PMID: 23033927
Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases.
Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Klepfish A, Shtalrid M, Berrebi A, Polliack A; Israeli CLL Study Group (ICLLSG). Shvidel L, et al. Among authors: polliack a. Ann Hematol. 2013 May;92(5):661-7. doi: 10.1007/s00277-012-1663-3. Epub 2012 Dec 29. Ann Hematol. 2013. PMID: 23274356
477 results